Valid MeSH ConditionsHTN-MortNCT07067632
Mortality Outcome of Controlled Blood Pressure Participants
An observational study of Valid MeSH Conditions and Hypertension (HTN), run by DejthidaNathaphong at 1 site in Thailand.
Trial summary
Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Valid MeSH Conditions, Hypertension (HTN)
- What is being tested?
- Antihypertensive treatment
- How many people
- 246,587 participants
- Where
- 1 siteThailand
- Study dates
- 1 Jul 2025to 29 Sep 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults ≥18 years with diagnosed hypertension Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg) Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Who may be able to join
- Adults ≥18 years with diagnosed hypertension
- Blood pressure controlled at target values defined by the study (e.g., <140/90 mmHg or <130/80 mmHg)
- Any comorbidity allowed unless the study focuses on pregnancy or pediatric population
Who cannot join
- Observational or retrospective studies
- Pediatric or pregnant participants
- Case reports, editorials, or conference abstracts without full data
- Studies not reporting mortality outcomes separately for controlled BP
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Mortality Outcome of Controlled Hypertension in Randomized Controlled or Open-label Study Intentionally Directed Intervention Effect Blood Pressure: A Systematic Review and Meta-Analysis
Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. This systematic review and meta-analysis aims to evaluate all-cause mortality and cardiovascular death among hypertensive patients who achieved BP targets in RCTs or open-label trials.
To determine whether achieving controlled blood pressure through intentional intervention (pharmacological or procedural) in RCTs or open-label studies reduces mortality (all-cause and cardiovascular) in hypertensive patients.
Read the detailed description
Sensitivity Analyses Excluding high-risk of bias studies Excluding short follow-up (<1 year)
- Conditions
- Valid MeSH Conditions, Hypertension (HTN)
- Being tested
- Antihypertensive treatment
- Keywords
- hypertension, cardiovascular death
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antihypertensive treatmentDrug
Also called device-based blood pressure lowering, lifestyle modification
Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP
Control groups receiving placebo, standard of care, or no intervention
| Study group | Role | What they receive |
|---|---|---|
| Antihypertensive treatment | Participants assigned to interventions (pharmacological, device-based, or lifestyle) directed at lowering blood pressure or Antihypertensive agents, Blood pressure-lowering treatment, Antihypertensive therapy. Receives: Drug: Antihypertensive treatment | |
| Control/Comparator | Participants receiving placebo, standard of care, or no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause mortality
All cause mortality by controlable hypertension treatment
Measured: 100 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start1 Jul 2025
- Primary completion29 Sep 2026
- Study completion29 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Valid MeSH ConditionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 246,587 participants (actual)
Sponsor and investigators
- Lead sponsor
- DejthidaNathaphong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nathaphong Dejthida, DejthidaNathaphong
- Investigators
- Nathaphong Dejthida, MD, Principal investigator, DejthidaNathaphong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07067632
- Sponsor's protocol ID
- DejthidaNathaphong
- Acronym
- HTN-Mort
- Status last verified
- Sep 2026
- First submitted
- 6 Jul 2025
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes